Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

742 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pedersen K, et al. Among authors: arribas j. Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581516
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J. Matar P, et al. Among authors: arribas j. Clin Cancer Res. 2004 Oct 1;10(19):6487-501. doi: 10.1158/1078-0432.CCR-04-0870. Clin Cancer Res. 2004. PMID: 15475436
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. Serra V, et al. Among authors: arribas j. Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385. Cancer Res. 2008. PMID: 18829560
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.
Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, Baselga J, Arribas J. Pedersen K, et al. Among authors: arribas j. Mol Cell Biol. 2009 Jun;29(12):3319-31. doi: 10.1128/MCB.01803-08. Epub 2009 Apr 13. Mol Cell Biol. 2009. PMID: 19364815 Free PMC article.
HER2 fragmentation and breast cancer stratification.
Arribas J, Parra-Palau JL, Pedersen K. Arribas J, et al. Clin Cancer Res. 2010 Aug 15;16(16):4071-3. doi: 10.1158/1078-0432.CCR-10-1501. Epub 2010 Aug 3. Clin Cancer Res. 2010. PMID: 20682714 Review.
A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J. Parra-Palau JL, et al. Among authors: arribas j. Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26. Cancer Res. 2010. PMID: 20978202
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. Serra V, et al. Among authors: arribas j. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31. Oncogene. 2011. PMID: 21278786 Free PMC article.
742 results